Administrative Core
行政核心
基本信息
- 批准号:10204118
- 负责人:
- 金额:$ 27.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-01 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdvanced DevelopmentAdvisory CommitteesAnticonvulsantsCalendarChemicalsCholinesterase InhibitorsCollaborationsCommittee MembersCommunicationCommunitiesDataDatabase Management SystemsDevelopmentEducational workshopEnsureEnvironmental HealthEquipment and supply inventoriesEventFederal GovernmentFosteringFundingGeneral PopulationGoalsGovernment AgenciesGrantHuman ResourcesIACUCIntellectual PropertyIntoxicationInvestigational DrugsIsoflurophateLaboratoriesLeadLeadershipLegal patentLogisticsManuscriptsMedical ResearchMissionMonitorOnline SystemsOrganophosphatesParaoxonPicrotoxinPoliciesProceduresProtocols documentationPubMedReadinessReagentRegulationReportingResearchResearch ActivityResearch InstituteResearch PersonnelResearch Project GrantsResource SharingRoleSafetySecureSecuritySeizuresSeriesSomanStrategic PlanningSystemTechnology TransferTherapeuticTherapeutic AgentsTimeLineTrainingUnited States Food and Drug AdministrationUnited States National Institutes of HealthUniversitiesWorkauthoritycentral databasechemical threatdata exchangedata managementdata sharingeducation researchimprovedinterestmedical countermeasuremeetingsnoveloperationpreventprogramsreceptorresearch and developmentstatisticssuccesssynergismtetramethylenedisulfotetraminetherapeutic developmentweb site
项目摘要
Project Summary – Administrative Core
The overall goal of the UC Davis CounterACT Center of Excellence is to identify and advance improved medical
countermeasures for stopping seizures and preventing long-term consequences of acute intoxication with
chemical threat agents, specifically organophosphate cholinesterase inhibitors like diisopropylfluorophosphate
(DFP), paraoxon and soman, or GABAA receptor blockers like tetramethylenedisulfotetramine (TETS) and
picrotoxin. The UC Davis CounterACT Center comprises three projects, three scientific cores, a research
education core and multiple committees — all of which must work closely together to ensure success. The role
of the Administrative Core is to oversee and coordinate the scientific and administrative operations of the
Center's activities and to foster interactions and synergism among Center research projects and scientific cores,
ultimately ensuring the Center meets annual milestones established in collaboration with NIH CounterACT
program officer(s). Additionally, the Administrative Core will coordinate interactions with the UC Davis
administration and external entities, such as the NIH CounterACT administration, the Center's External Advisory
Committee, the larger CounterACT research community, the U.S. Food and Drug Administration (FDA), the
Biomedical Advanced Research and Development Authority (BARDA), and commercial partners. The Core's
objectives are: (1) Develop a strategic plan for achieving annual Center milestones and ensure its effective and
efficient implementation; (2) Provide scientific leadership and logistical support to coordinate and integrate
Center activities and promote interactions among Center investigators; (3) Facilitate data and resource sharing
among Center investigators and other CounterACT investigators; (4) Provide budgetary oversight and grant
management; (5) Ensure the safety and security of personnel, materials, data and facilities; (6) Coordinate the
development of intellectual property (IP) strategies and the transitioning of leads for advanced development; (7)
Coordinate with FDA, BARDA and other federal government agencies; and (8) Identify, engage and coordinate
communications with commercial partners.
项目摘要-行政核心
加州大学戴维斯分校CounterACT卓越中心的总体目标是确定和推进改善医疗
制止癫痫发作和预防急性中毒的长期后果的对策
化学威胁剂,特别是有机磷酸胆碱酯酶抑制剂,如二异丙基氟磷酸盐
(DFP)、对氧磷和梭曼,或GABAA受体阻断剂如四亚甲基二磺基四胺(TETS)和
印防己毒素加州大学戴维斯分校反ACT中心包括三个项目,三个科学核心,一个研究
教育核心和多个委员会--所有这些都必须密切合作,以确保成功。的作用
的行政核心是监督和协调科学和行政运作的
中心的活动,并促进中心研究项目和科学核心之间的互动和协同作用,
最终确保中心达到与NIH CounterACT合作建立的年度里程碑
程序员(S)。此外,行政核心将协调与加州大学戴维斯分校的互动
管理和外部实体,如NIH CounterACT管理,中心的外部咨询
委员会,更大的反ACT研究社区,美国食品和药物管理局(FDA),
生物医学高级研究和发展管理局(巴尔达)和商业合作伙伴。该芯体的
目标是:(1)制定实现中心年度里程碑的战略计划,并确保其有效性和
(2)提供科学的领导和后勤支持,以协调和整合
中心活动,促进中心研究者之间的互动;(3)促进数据和资源共享
(4)提供预算监督和拨款
(五)确保人员、物资、数据和设施的安全;(六)协调
制定知识产权(IP)战略,并为高级开发转移线索;(7)
与FDA、巴尔达和其他联邦政府机构协调;以及(8)识别、参与和协调
与商业伙伴的沟通。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pamela J Lein其他文献
Pamela J Lein的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pamela J Lein', 18)}}的其他基金
Project 1: Reduction of Pro-Inflammatory Signaling
项目 1:减少促炎症信号传导
- 批准号:
10684082 - 财政年份:2022
- 资助金额:
$ 27.48万 - 项目类别:
Ketogenic diet approaches to slow disease progression in a rat model of Alzheimer's disease
生酮饮食方法可减缓阿尔茨海默病大鼠模型的疾病进展
- 批准号:
9977496 - 财政年份:2020
- 资助金额:
$ 27.48万 - 项目类别:
Identifying Molecular Targets for the Proconvulsant Activity of TETS
确定 TETS 促惊厥活性的分子靶点
- 批准号:
9905564 - 财政年份:2019
- 资助金额:
$ 27.48万 - 项目类别:
Does air pollution increase risk of AD in a genetically susceptible animal model?
空气污染是否会增加遗传易感动物模型患 AD 的风险?
- 批准号:
9126737 - 财政年份:2016
- 资助金额:
$ 27.48万 - 项目类别:
Mitigation of Neurological Damage Following Seizures
减轻癫痫发作后的神经损伤
- 批准号:
10204125 - 财政年份:2012
- 资助金额:
$ 27.48万 - 项目类别:
Novel anticonvulsant and neuroprotective therapies for TETS and OP intoxication
针对 TETS 和 OP 中毒的新型抗惊厥药和神经保护疗法
- 批准号:
9142832 - 财政年份:2012
- 资助金额:
$ 27.48万 - 项目类别:
Novel Anticonvulsant and Neuroprotective Therapies for TETS and OP Intoxication
针对 TETS 和 OP 中毒的新型抗惊厥和神经保护疗法
- 批准号:
10204117 - 财政年份:2012
- 资助金额:
$ 27.48万 - 项目类别:
Novel anticonvulsant and neuroprotective therapies for TETS and OP intoxication
针对 TETS 和 OP 中毒的新型抗惊厥药和神经保护疗法
- 批准号:
8925299 - 财政年份:2012
- 资助金额:
$ 27.48万 - 项目类别:
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 27.48万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 27.48万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 27.48万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 27.48万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 27.48万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 27.48万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 27.48万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 27.48万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 27.48万 - 项目类别:














{{item.name}}会员




